



Review On: Uses of Taxane in Various Diseases

S Singh*, V Lambole, V Gajera, D.Shah

Department of pharmacology, Shree Naranjibhai Lalbhai Patel College of Pharmacy, Umrahk, Gujarat, India.

*Corresponding author's E-mail: serenesneha91@gmail.com

Received: 14-02-2021; Revised: 21-03-2021; Accepted: 28-03-2020; Published on: 20-04-2021.

ABSTRACT

Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting adverse effect of taxanes used to treat breast cancer, prostate cancer, cervical cancer, ovarian cancer. The taxanes are among the most active cytotoxic agents in oncology and are widely used in adjuvant and advanced treatment settings in multiple tumour types. In this review article few and the toxicity related to taxane has been shown. Such as TAPS, Arthralgia, Myalgia, Neurotoxicity, Hypersensitivity, Peripheral neuropathy, Bone marrow toxicity. Paclitaxel and docetaxel are standard therapies in advanced non-small-cell lung cancer (NSCLC) and are increasingly used in earlier treatment settings. The taxanes are generally well tolerated but can be associated with severe, irreversible (and rarely life-threatening) toxicity. Premedication and special infusion sets are necessary to reduce the risk of hypersensitivity reactions. Newer taxanes are in development designed to improve the therapeutic index and ease of administration. Several agents have completed phase I/II clinical trials and are in phase III testing. Many other novel taxanes are at earlier stages of development and appear promising as single agents and in combination regimens. Safer and more effective taxanes could replace paclitaxel and docetaxel as standard treatments in NSCLC. Over the course of taxane chemotherapy and possibly improve taxane adherence in women with breast cancer. These findings, as well as whether exercise can attenuate CIPN by the end of taxane chemotherapy, should be confirmed in larger trials. The combination of a taxane, paclitaxel or docetaxel, and a platinum compound has become the systemic chemotherapy of choice for primary ovarian cancer and has demonstrated high efficacy.

Keywords: Taxane, cancer, Neurotoxicity, Peripheral neuropathy, Bone marrow toxicity.

QUICK RESPONSE CODE →

DOI:

10.47583/ijpsrr.2021.v67i02.030



DOI link: <http://dx.doi.org/10.47583/ijpsrr.2021.v67i02.030>

INTRODUCTION

The taxanes in clinical use embrace paclitaxel (Taxol, Bristol-Myers Squibb) and docetaxel (Taxotere, Sanofi-Aventis)¹. Taxanes square measure a category of therapy agents that promote the chemical change of tubulin into extremely stable, intracellular microtubules. These microtubules cause necrobiosis by officious with traditional cellular division. The primary taxane developed and tested within the field of medical specialty was paclitaxel. The introduction of paclitaxel to the aggregation of medical specialty medical aid within the early Nineties had an excellent impact on the quality of care in respiratory organ cancer, breast cancer, gonad cancer, and different solid tumors, beyond this development, another taxane, docetaxel, was introduced.

These agents became a major element of cancer care within the treatment of each early-stage sickness and advanced sickness. The progressive advantage of their effectualness relative to antecedently commonplace medical aid seems to be clear; survival time is enlarged

with the employment of taxane medical aid in cancer of the respiratory organ, breast, and ovary. As a result, taxanes are wide used over the past decade within the management of those solid tumors. as an example, the mixture of paclitaxel and carboplatin has become the foremost ordinarily used regimen in patients with advanced non small cell respiratory organ cancer (NSCLC). Unfortunately, taxane medical aid is related to aspect effects like peripheral pathology, myelosuppression, arthralgias, myalgias, and skin reactions which will adversely have an effect on patient-reported quality of life (QOL). Peripheral pathology will be severe. This toxicity is additive across the course of medical aid, will be a dose-limiting toxicity, and should result in dose reduction or stop of medical aid.

Thus, we tend to still be during a treatment era during which agents known to boost clinical endpoints like response rate, time to treatment failure, and overall survival are related to life-altering, and typically permanent, considerations stemming from neuropathic drug effects, pain, and incapacity. If one is to realize a way of the general good thing about medical aid, the acute and long toxicities should be balanced against the effectualness of treatment².

Effects of Taxane on Non-small Lung Cancer

Taxane therapy has been a very important a part of non-small cell lung cancer (NSCLC) treatment since paclitaxel and docetaxel were 1st approved by the Food and Drug



Administration within the late Nineties. Paclitaxel and docetaxel are normally employed in treating advanced sickness together with platinum and non platinum agents within the first-line setting, as single agents in patients with poor performance standing (PS) in second-line settings, and together with radiation in regionally advanced sickness. Taxanes also are more and more getting used within the adjuvant setting, as prompt by a survey of nearly three hundred America oncologists,³ and in current randomised trials. Taxanes cause mitotic arrest in cancer cells by stabilizing microtubules and preventing depolymerization. Paclitaxel and docetaxel disagree in binding affinities and pharmacology,⁴ however similar levels of activity in NSCLC. In patients with antecedently untreated advanced NSCLC, paclitaxel/ noble metal and docetaxel/platinum doublets lead to objective responses in 20%-30% of patients, 1-year survival in 30%-40%, and 8-10 month median overall survival (OS).⁵⁻⁸ Similar effectuality has been seen with non platinum taxane regimens in randomised trials.⁹⁻¹²

Effects of taxane on ovarian cancer

Ovarian cancer continues to be a major supply of morbidity and mortality. Survival correlates with the stage of ovarian cancer at diagnosis: 5-year survival for localized cancer is ninety four compared to twenty ninth for patients with distant metastases¹³. Best treatment for ovarian cancer involves cytoreduction followed by general therapy, generally with six cycles of a taxane combined with a platinum agent¹⁴. In 2 irregular studies of advanced ovarian cancer, paclitaxel/ cisplatin resulted in considerably longer progression-free survival (PFS) and overall survival (OS) than the cyclophosphamide/ cisplatin arm.^{15,16} As a result of most responders can relapse inside eighteen months when finishing first-line medical care, ovarian cancer is progressively recognized as a chronic malady characterized by the serial administration of active agents. Whereas many agents are accessible for the treatment of relapsed malady, response rates fall with every future relapse diseases to the event of drug resistance. One potential strategy to higher utilize existing treatment choices is to increase growth response through maintenance therapy; this approach ultimately might improve patient outcome¹⁷. The conception of continuous therapy on the far side four to six cycles of treatment could be a polemic strategy within the management of solid tumors¹⁸⁻²⁰. The principle for this approach is that nonresistant, slowly dividing growth cells that were inadequately exposed to cycle-dependent cytotoxic agents throughout the initial treatment amount is also considerably reduced in variety or utterly eliminated with the continuation of therapy²¹. Additionally, bound antineoplastic agents, as well as paclitaxel, have profound anti angiogenic effects that will be schedule dependent.^{22,23} As a result, continuation of therapy delays growth by targeting each the growth vasculature and remaining cancer cells. Whereas restricted irregular trial information did not show any advantage for added treatments or consolidation medical care in ovarian

cancer,²⁴⁻²⁶ nonrandomized trials indicate that prolonged treatment with paclitaxel might have some profit.^{27, 28} A future irregular study scrutiny three vs. twelve months of paclitaxel maintenance medical care in patients with a whole response to primary medical care incontestable prolonged PFS within the 12-month arm. However, any advantage of maintenance therapy, whether or not associate redoubled objective response rate or prolonged PFS or OS, should be balanced against the intercalary toxicity and potential impact on patients' quality of life (QOL) related to extra therapy. Novel taxanes presently accessible or below development might prove helpful in maintenance therapy due to the potential for reduced toxicity, bigger growth property, and favorable impact on QOL.

Effects of Taxane on Prostate Cancer

Despite important initial responses to androgen deprivation therapy, most metastatic patients attain associate degree incurable castration-resistant prostate cancer (mCRPC).^{29,30} Several medication are approved for the treatment of mCRPC, together with taxanes, and androgen receptor (AR) communication inhibitors^{30,31}. Sadly, in patients about to these agents, only a few therapeutic choices are accessible, though platinum-based treatments have incontestable a restricted profit in patients with aggressive variant prostate cancer (PC)³²⁻³⁴. prophetic markers are required to work out the most effective treatment for patients antecedently treated with taxanes or AR communication inhibitors. Taxanes bind tubulin-inhibiting cell division however conjointly AR nuclear translocation, reducing AR communication.³⁵⁻³⁷ Many factors are related to taxane resistance, together with expression of b-tubulin iso-forms and activation of drug flow pumps. PTEN loss and activation of PI3K/AKT/mTOR, MAPK, and NF-kB have conjointly been related to taxane resistance.^{38,39} Whereas noble metal agents aren't used habitually for the treatment of mCRPC, there's associate degree increasing use of those agents, particularly in patients with small-cell or system neoplasm variants. In fact, some antineoplastic activity has been represented for carboplatin, cisplatin, and satraplatin in mCRPC patients.⁴⁰ sadly, molecular biomarkers to spot mCRPC patients World Health Organization may benefit from these drug combos stay elusive. The unfinished understanding of the molecular mechanisms of taxane resistance limits the identification of vulnerabilities and potential therapeutic targets. Here, wanted to elucidate the mechanistic basis and response indicators for the synergistic antineoplastic effectualness of taxane-platinum combos in advanced computer (Supplementary. Mining of human computer datasets to check the transcriptomes of taxane-exposed and taxane-naïve patients showed a marked down regulation of CXCR2 and BCL-2 in taxane-exposed patients. Mechanistically, we tend to showed that taxanes induce CXCR2 and BCL-2 down regulation. Further, we tend to incontestable that CXCR2 and BCL-2 verify cisplatin sensitivity which targeting them sensitizes computer cells to cisplatin. Finally, in vivo diagnosis



knowledge testing shows that taxane-platinum combos are extremely synergistic which previous exposure to taxanes sensitizes mCRPC tumors to cisplatin. Together, our knowledge establishes associate degree non-heritable vulnerability in taxane-treated mCRPC patients with a possible prophetic price for platinum-based drug combinations.⁴¹

Effects of Taxane on Cervical Cancer

Cervical cancer is one of the most common malignancies diagnosed during pregnancy with an estimated incidence of 1:2000–10,000 pregnancies. Discrepancies in inclusion criteria, such as live births, births beyond 20 weeks etc, may explain the variation of these results. Moreover, an underestimation of the incidence of cervical cancer diagnosed during pregnancy may be due to lack of data of pregnancies that ended in a miscarriage or induced abortion. Management of cervical cancer during pregnancy represents a challenge for physicians due to its low incidence and to the lack of strong data. Multidisciplinary decision must be made taking into consideration the women's desire to retain gestation instead of terminating their pregnancy. Several studies support the use of taxanes, especially paclitaxel, in combination with platinum derivatives as chemotherapy regimens. Even though there are accumulating data in literature defending taxanes administration during the second and third trimester of pregnancy, their use remains controversial. Adding taxanes in Neo adjuvant Chemotherapy (NACT) schemes is a recent initiative; hence, there are still many questions regarding its safety for both women and neonates. The first systematic review and meta-analysis incorporating all available data from literature and evaluating the effectiveness and safety of taxanes administration in cervical cancer during pregnancy. The systematic review and meta-analysis was performed in accordance with the PRISMA guidelines. All studies investigating the effectiveness and safety of taxanes (combined with platinum derivatives) when administered in cervical cancer during pregnancy, no matter of sample size, were eligible. From each one of studies, the following data were extracted: first author, year of publication, chemotherapy regimen and agents administered during pregnancy, number of patients treated, patient age at diagnosis, FIGO stage at pregnancy, gestational age (GA) at diagnosis, pathological type (squamous, adenocarcinoma etc.), grade, GA at first cycle of chemotherapy administration, complete or partial response to chemotherapy, GA at delivery, way of delivery (cesarean section, etc.), pathological evaluation of the placenta, fetal outcome, weight at delivery, adverse effects of chemotherapy during pregnancy, treatment after pregnancy, overall survival (OS) in months, progression free survival (PFS) in months.

The use of taxanes in combination with platinum derivatives resulted in the birth of alive neonates in all cases and there was not any miscarriage. Paclitaxel was administered in all identified pregnancies with the addition

of cisplatin in 13 pregnancies (13 newborns) and of carboplatin in only one retrieved case (1 newborn). The mean age of cervical cancer patients at diagnosis was 32.4 years (SD: 4.6; median: 32.4; range: 26–39). In 85.7% of cases (12/ 14) a diagnosis of squamous cell carcinoma was established; whereas, in only one case (7.2% of cases) adenocarcinoma was diagnosed; one more case was also present (7.2% of cases) of small cell neuroendocrine carcinoma. The FIGO stage at diagnosis in pregnancy was early (FIGO stage I & II) in all cases except one with no available data. The mean GA at cervical cancer diagnosis was 22.9 weeks of gestation (SD: 5.6; median: 25; range: 13–29.4), whereas the mean GA at chemotherapy administration was 26.4 weeks (SD: 3.9; median 26.7; range: 18–30.6). Data regarding EPO and/or G-CSF administration during the pregnancy were not provided. Complete response (CR) to chemotherapy administered during pregnancy was achieved in only one case (7.2% of cases) whilst partial response (PR) was achieved in 92.9% some cases. Taxanes administration during the 2nd and 3rd trimester of pregnancy is a safe choice.⁴²

Effects of Taxane on Breast Cancer

Chemotherapy-induced peripheral neuropathy (CIPN) could be a dose-limiting adverse impact of taxanes accustomed treat carcinoma. Women (n ¼ 27) were irregular to immediate exercise (IE, throughout taxane chemotherapy) or delayed exercise (DE, when chemotherapy). Supervised aerobic, resistance, and balance coaching was offered three days per week for 8-12 weeks. Supervised aerobic, resistance, and balance coaching was offered three days per week for 8-12 weeks. CIPN symptoms and quality of life were assessed exploitation the European Organization for Research and Treatment of Cancer Quality of Life form (EORTC QLQ) C30 and CIPN20 (scored from zero to 100). The proportion of participants reportage moderate to severe sensory symptoms ('3/4' or '4/4' for CIPN20 sensory items) was conjointly evaluated, beside clinical sensory testing at the lower limb (vibration sense and pinprick). Taxane treatment adherence, as well as relative dose intensity, was extracted from patient medical records. Assessments occurred at: baseline (before taxane chemotherapy), pre-cycle four (before the ultimate taxane cycle), the tip of therapy, and follow-up (10-15 weeks when therapy). Exercise might attenuate CIPN over the course of taxane therapy and probably improve taxane adherence in girls with carcinoma. Chemotherapy-induced peripheral pathology (CIPN) could be a common non-hematologic adverse impact of choose antineoplastic agents, as well as taxanes. Taxanes, particularly docetaxel and paclitaxel, square measure of prescribed as a element of contemporary carcinoma multi-agent therapy regimens and up to eightieth of girls with carcinoma might expertise CIPN symptoms up to a pair of years when paclitaxel treatment. CIPN from taxane based therapy is primarily sensory pathology, manifesting as symptom, numbness, or pain within the hands and feet, with the thick medullated nerve fibers liable for vibration sensation and sense of



position being primarily affected. Further, girls treated with taxanes for carcinoma World Health Organization report higher pretreatment levels of moderate to vigorous physical activity square measure at a lower risk of CIPN.⁴³

The taxanes had a special clinical development profile in breast cancer 1st phase I studies with paclitaxel were rumored in 1986 – 1987. However the event of paclitaxel was bogged down by hypersensitivity reactions requiring the systematic use of premedication. This became commonplace for paclitaxel. Regarding docetaxel, the clinical development started later with initial phase I studies. From the conclusions of those early phase I taxane studies, vital messages ought to be integrated for interpretation of the clinical trial results victimization taxanes as monotherapy or combination regimens in pathological process and adjuvant carcinoma. The vital conclusion from all phase I trials regarding paclitaxel was that no specific schedule and dose emerged because the optimum means of victimization this agent for any development in phase II and III studies, so making confusion for many years once making an attempt to outline the optimum efficacy–toxicity quantitative relation. The results of completed studies with paclitaxel and docetaxel provided adequate proof to justify the utilization of a single-agent taxane in patients with antecedently treated and untreated pathological process carcinoma with Taxane mono chemotherapy.

The taxanes have entered our clinical apply and may be thought-about as a regular medical care in pathological process carcinoma, either in mono- or in polychemotherapy. Their role together with anthracyclines as first-line medical care of advanced carcinoma is rising with knowledge showing that the clinical good thing about docetaxel and antibiotic drug may well be superior to classical anthracycline-containing poly chemotherapy (AC). Although this good thing about un wellness management could also be true for high risk pathological process patients (visceral metastases, speedily progressing advanced unwellness etc.), survival knowledge don't show any important advantage for either medical care, largely associated with crossover processes. Yet, a great deal of results recommends that not exposing patients (with therapy indication) to taxanes during their unwellness could also be damaging to their outcome. The taxanes have inflated the survival of advanced carcinoma however don't appear, so far, to extend the characteristic of pathological process carcinoma.

The results of the adjuvant trials additionally shed a replacement light-weight on the clinical role of taxanes. It's currently turning into clear that either paclitaxel or docetaxel area unit causing substantial advantages in terms of DFS (disease-free survival) and OS (overall survival). Paclitaxel in sequence (AC followed by paclitaxel) and docetaxel each together (TAC) and sequence (FEC followed by docetaxel) area unit showing superior results to anthracycline-containing regimens. This can be confirming the aptitude for the taxanes to impact the

explanation of carcinoma. Today, taxanes ought to be thought-about, in clinical apply, as a part of the therapeutic assemblage for the adjuvant treatment of patients with node-positive breast cancer.⁴⁴

Toxicity Associated with Taxane: TAPS

TAPS (Taxane Acute Pain Syndrome) is a common early toxicity associated with taxane-based chemotherapy. It may affect the patient's quality of life, resulting in chemotherapy treatment modification and/or the need for pharmacologic interventions. Currently no "gold standard" treatment is available for TAPS; however, symptomatic treatment with NSAIDs, opioids, and corticosteroids are common interventions. The use of antiepileptics, such as gabapentin or pregabalin, is an intriguing treatment option, because TAPS may be related to sensory nerve toxicity. Effective management of TAPS is paramount for optimizing the oncologic treatment of patients who receive taxanes, particularly considering the suggested association between TAPS and the subsequent event of taxane-induced peripheral neuropathy. Further studies are needed to identify optimal assessment and treatment strategies for TAPS.⁴⁵

Taxane Induced Arthralgia and Myalgia

Arthralgia and Myalgia following taxane therapy has been documented within the literature. However, these 2 toxicities related to taxane treatment haven't been closely examined within the literature, and knowledge stay inconsistent in terms of the according incidences of those toxicities. the aim of this literature review was to supply a a lot of comprehensive understanding of the incidence of taxane-induced pain and pain, moreover on document the danger factors and preventative and therapeutic treatments that are investigated the 2 main commercially on the market taxanes, paclitaxel and docetaxel, square measure each wide utilized in the medical specialty setting. More recently, albumin-bound paclitaxel (nab-paclitaxel) has additionally emerged as associate approved taxane drug for the treatment of pathologic process carcinoma. Though taxanes square measure fairly well tolerated, they will cause some distressing and heavy aspect effects. Abundant of the literature has targeted on documenting toxicities like leucopenia and phalacroscisa number of the foremost serious and customary adverse effects of taxane treatment. However, there's a scarcity of studies specializing in taxane-induced pain (joint pain) and pain (muscle pain). As such, knowledge stay inconsistent in terms of the according incidences of those toxicities, and knowledge for preventive medical aid for pain and pain square measure scarce. The current work aimed to document the findings on taxane-induced pain and pain according within the literature. Arthralgia and Myalgia following taxane therapy usually begins 24–48 h once the completion of taxane medical aid and square measure usually delineate as flu-like symptoms. Signs and symptoms usually last around 3 to 5 days, and patients treated with docetaxel usually report a lower incidence of pain and pain than once treated with paclitaxel. This



systematic review documents a group of articles coverage the incidence of pain and pain in patients once taxane therapy. The according incidences of pain and pain square measure non-uniform and varied. The author recommends that a prospective study be tired order to higher perceive verity incidence of joint and muscle pain in patients undergoing taxane therapy with docetaxel, paclitaxel, or nab-paclitaxel. Taxane therapy is related to larger incidences of pain and pain than non-taxane styles of therapy. Moreover, docetaxel and nab-paclitaxel appear to be related to lower incidences of pain and pain than paclitaxel. Finally, the literature on interference and therapeutic treatment of taxane-induced pain and pain is scarce. a lot of studies ought to be tired order to a lot of once and for all establish optimum therapeutic and preventative treatments.⁴⁶

Neurotoxicity with Taxane

The clinical use of taxanes can be restricted by neurotoxicity, Few determination in each clinical and electrophysiological medical specialty functions in fourteen patients treated with paclitaxel/cisplatin (cumulative paclitaxel doses 175-1225 mg/m', accumulative cisplatin doses 100-700 mg/m') and in half dozen patients treated with docetaxel (cumulative doses 100-400 mg/m'). Among the paclitaxel/cisplatin cluster, twelve patients developed sensory symptoms. Extra weakness was seen in eight patients, however nervous conductivity studies of the leg bone nerve disclosed impaired perform in thirteen patients. 3 courses of docetaxel resulted in sensory neuropathy and a decrease in orthodromic sensory conductivity speed of the lateral region nerve in J patients. Docetaxel failed to lead to clinical motor pathology or altered nervous conductivity of the leg bone nerve. In each teams, severity of clinical and electrophysiological neurotoxicity progredient increased with accumulative humorous doses. Lastly, patients treated with paclitaxel/cisplatin developed sensory and motor pathology, whereas patients treated with docetaxel solely developed sensory pathology. Careful medical specialty and electrophysiological observation would possibly permit to sight early symptoms of neurotoxicity and so to avoid severe neurotoxicity.⁴⁷

Hypersensitivity Reaction with Taxane

The most characteristic toxicity related to taxane medical aid is that the high incidence of hypersensitivity reactions. Most investigators have attributed the substantial risk of hypersensitive reactions related to paclitaxel administration to the desired presence of cremophor, the substance required for this agent once it's used clinically. This aspect result was notably problematic throughout the initial development of paclitaxel. Overtime was documented, and it absolutely was unsure at that point whether or not such events resulted from severe drug-related hypersensitivity or could be caused by poorly characterized paclitaxel induced viscous toxicity (e.g., bodily cavity arrhythmias). future expertise unconcealed that single-agent paclitaxel was terribly seldom related to

serious viscous aspect effects which the severe manifestations of hypersensitivity may well be prevented in most patients by pretreatment with H-1- and H-2-blocking agents, and with corticosteroids. whereas in early clinical trials the corticosteroids, sometimes anti-inflammatory, got a minimum of twelve h before paclitaxel, substantial clinical knowledge have a lot of recently unconcealed that once one dose of anti-inflammatory is run at constant time because the histamine-blocking medication similar levels of protection from the a lot of serious allergic effects of the antineoplastic agent is obtained. For those people World Health Organization develop manifestations of immediate-type hypersensitivity (e.g., cardiovascular disease, cardiovascular disease, diffuse erythroderma, severe anxiety, dyspnea), it's currently recognized that ninetieth is with success treated with the agent if the infusion is quickly out of print once the initial signs/symptoms are determined (almost perpetually <1–2 min once initiation of the paclitaxel infusion) then restarted around thirty min later. this can be presumptively as a result of the initial reaction depletes the system of relevant mediators of hypersensitivity (e.g., "mast cell degranulation"), that then take some poorly outlined amount of your time to recover sufficiently to lead to a future reaction. For the less common state of affairs of symptoms revenant once the infusion is started a second time, a range of "desensitization programs" are developed to allow self-made treatment with paclitaxel. Docetaxel, despite not being developed in cremophor, is usually related to the event of hypersensitivity reactions. Fortuitously, like paclitaxel, these events seldom lead to conclusion of treatment. Customary bar against docetaxel hypersensitivity reactions differs from that used with paclitaxel, patients habitually receiving many oral doses of anti-inflammatory (for 3–5 days) instead of one blood vessel administration of corticosteroids together with histamine-blocking agents. This procedure additionally protects patients against the event of docetaxel-associated fluid retention.⁴⁸

Peripheral Neuropathy with Taxane

Both paclitaxel and docetaxel are potentially neurotoxin agents, though recent trial expertise has incontestable that this toxicity may be a lot of serious concern with paclitaxel, a minimum of once the taxane is combined with another toxin agent (e.g., carboplatin). Within the case of paclitaxel, the incidence and severity of pathology seem to be associated with each the height concern concentration of the drug and also the total length of treatment. For instance, the incidence of clinically relevant peripheral pathology is bigger once the agent is infused over 3h instead of 24 h, significantly once the drug is combined with another neurotoxin antineoplastic agent, like cisplatin. There's presently no proof, supported the results of randomised trials, to point out that any drug will forestall or reverse the toxin effects of the taxanes. Fortunately would have it, once this aspect impact happens it's sometimes reversible over time following



discontinuance of the taxane. Patients with pre-existent peripheral pathology (e.g., as a results of diabetes or alcohol) could also be significantly susceptible to the neurotoxic effects of those agents. In such an individual if a taxane is to use as a part of medical care docetaxel could also be the popular drug owing to a lower risk of treatment-related neurotoxicity.⁴⁸

Bone Marrow Toxicity with Taxane

During its early clinical development, paclitaxel was most administered as a 24-h infusion, in a trial to limit the incidence of significant hypersensitivity Reactions. On this schedule, paclitaxel, a cyclespecific drug, was related to a high incidence of bone marrow suppression (principally neutropenia). Sequent studies disclosed that 3-h paclitaxel infusion regimens were related to similar levels of antineoplastic activity, no higher incidence of hypersensitivity reactions, and considerably less neutropenia. As a result, in most clinical settings, paclitaxel is presently delivered as a shorter infusion (e.g., 1–3 h). In normal clinical usage, docetaxel has been delivered as a 1-h infusion at doses starting from 60– a hundred mg/m². Grade four neutropenia unremarkably accompanies docetaxel delivered as one agent or together regimens. Severe blood disorder is Associate in nursing uncommon aspect result of each commercially available taxanes. Together therapy programs, notably once paclitaxel and docetaxel are administered with carboplatin, vital living substance count depression will sometimes be determined. Once specific taxane-containing regimens are famous to be related to the assembly of severe neutropenia, the prophylactic use of bone marrow colony-stimulatory factors (e.g., G-CSF, GM-CSF) has become a customary part of treatment. Or else, the initial course is also delivered while not CSF support, with sequent courses delivered at a reduced dose level or with CSF support if severe neutropenia is determined.⁴⁸

CONCLUSION

In summary, this review incontestable that Taxane, that is of course found in *Taxus baccata* and could be a major elements, presents totally different properties which will be helpful each within the ovarian cancer, Breast cancer, cervical cancer, prostate cancer treatment and bar of various forms of toxicity like Bone marrow toxicity, neuropathy with taxane, hypersensitivity reaction, neurotoxicity, arthralgia and myalgia besides exerting outstanding role in drug absorption. While both paclitaxel and docetaxel can cause clinically relevant side effects, in general these can be successfully managed in most patients. It is rare for an individual receiving a taxane to be required to have the treatment discontinued secondary to excessive toxicity.

REFERENCES

- Nabors LB, Surboeck B, Grisold W, Complications from pharmacotherapy. *Handb Clin Neurol*, 2016; 134:235-250. DOI:10.1016/B978-0-12-802997-8.00014-1; PMID:26948358.
- Cella D, Peterman A, Hudgens S, Webster K, Socinski MA. Measuring the side effects of taxane therapy in oncology: the functional assessment of cancer therapy-taxane (FACT-taxane). *Cancer*. 2003 Aug 15;98(4):822-31. DOI: 10.1002/cncr.11578; PMID: 12910528.
- Green MR, Andrews M, Leff R, Willey J, Allegra C, Denes A, Epstein J, Jones J, Lokey L. Adjuvant Therapy Choices in Patients With Resected Non-Small-Cell Lung Cancer: Correlation of Doctors' Treatment Plans and Relevant Phase III Trial Data. *J Oncol Pract*. 2005 Jul;1(2):37-42. doi: 10.1200/JOP.2005.1.2.37, PMID: 20871677.
- Lam Y, Chan C, Kuhn J, Pharmacokinetics and pharmacodynamics of the taxanes. *J Clin Pharm Pract* 1997; 3:76-93. Doi: 10.1177/107815529700300202.
- Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. *J Clin Oncol*. 2003 Aug 15; 21(16):3016-24. doi: 10.1200/JCO.2003.12.046, PMID: 12837811.
- Kelly K, Crowley J, Bunn PA Jr, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. *J Clin Oncol*. 2001 Jul 1; 19(13):3210-8. doi: 10.1200/JCO.2001.19.13.3210, PMID: 11432888.
- Schiller JH, Harrington D, Belani CP, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. *N Engl J Med*, 2002; 346:92-8, DOI: 10.1056/NEJMoa011954.
- Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, Matano E, Boni C, Marangolo M, Failla G, Altavilla G, Adamo V, Ceribelli A, Clerici M, Di Costanzo F, Frontini L, Tonato M; Italian Lung Cancer Project. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. *J Clin Oncol*. 2002 Nov 1;20(21):4285-91. doi: 10.1200/JCO.2002.02.068, PMID: 12409326.
- Georgoulas V, Ardavanis A, Tsiadaki X, Agelidou A, Mixalopoulou P, Anagnostopoulou O, Ziotopoulos P, Toubis M, Syrigos K, Samaras N, Polyzos A, Christou A, Kakolyris S, Kouroussis C, Androulakis N, Samonis G, Chatzidaki D. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. *J Clin Oncol*. 2005 May 1;23(13):2937-45. doi: 10.1200/JCO.2005.04.016, PMID: 15728228.
- Smit EF, van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F, Smit H, Gaafar R, Biesma B, Manegold C, Neymark N, Giaccone G; European Organization for Research and Treatment of Cancer Lung Cancer Group. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. *J Clin Oncol*. 2003 Nov 1;21(21):3909-17. DOI: 10.1200/JCO.2003.03.195, PMID: 14581415.
- Kosmidis P, Mylonakis N, Nicolaides C, Kalophonos C, Samantas E, Boukovinas J, Fountzilias G, Skarlos D, Economopoulos T, Tsavdaridis D, Papakostas P, Bacoyiannis C, Dimopoulos M. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. *J Clin Oncol*. 2002 Sep 1;20(17):3578-85. DOI: 10.1200/JCO.2002.12.112, PMID: 12202657.
- Treat JA, Gonin R, Socinski MA, Edelman MJ, Catalano RB, Marinucci DM, Ansari R, Gillenwater HH, Rowland KM, Comis RL, Obasaju CK, Belani CP; Alpha Oncology Research Network. A randomized, phase



- III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer. *Ann Oncol*. 2010 Mar;21(3):540-547. DOI: 10.1093/annonc/mdp352, PMID: 19833819.
13. Cancer Facts and Figures. American Cancer Society, 2005.
 14. Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, Jiang C, Alberts D; Southwest Oncology Group; Gynecologic Oncology Group. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. *J Clin Oncol*. 2003 Jul 1;21(13):2460-5. DOI: 10.1200/JCO.2003.07.013, PMID: 12829663.
 15. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). *Semin Oncol*. 1996 Oct;23(5 Suppl 12):40-7, PMID: 8941409.
 16. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. *J Natl Cancer Inst*. 2000 May 3;92(9):699-708. DOI: 10.1093/jnci/92.9.699, PMID: 10793106.
 17. Ozols RF. Maintenance therapy in advanced ovarian cancer: progression-free survival and clinical benefit. *J Clin Oncol*. 2003 Jul 1;21(13):2451-3. DOI: 10.1200/JCO.2003.03.039, PMID: 12829660.
 18. Einhorn LH, Williams SD, Loehrer PJ, Birch R, Drasga R, Omura G, Greco FA. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. *J Clin Oncol*. 1989 Mar;7(3):387-91. DOI: 10.1200/JCO.1989.7.3.387. PMID: 2465391.
 19. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. *Lancet*. 1998 Sep 19; 352(9132):930-42. PMID: 9752815.
 20. Coates A, GebSKI V, Bishop JF, Jeal PN, Woods RL, Snyder R, Tattersall MH, Byrne M, Harvey V, Gill G. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. *N Engl J Med*. 1987 Dec 10; 317(24):1490-5. DOI: 10.1056/NEJM198712103172402, PMID: 3683485.
 21. Rowinsky EK, Donehower RC. Paclitaxel (taxol). *N Engl J Med*. 1995 Apr 13;332(15):1004-14. doi: 10.1056/NEJM199504133321507. Erratum in: *N Engl J Med* 1995 Jul 6; 333(1):75. PMID: 7885406.
 22. Browder T, Butterfield CE, Kräling BM, Shi B, Marshall B, O'Reilly MS, Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. *Cancer Res*. 2000 Apr 1; 60(7):1878-86. PMID: 10766175.
 23. Miller KD.; Sweeney CJ.; Sledge Jr GW.; Redefining the target: chemotherapeutics as anti angiogenics, *J Clin Oncol*, 19(4), 2001, 1195–206.
 24. Hakes TB, Chalas E, Hoskins WJ, Jones WB, Markman M, Rubin SC, Chapman D, Almadrones L, Lewis JL Jr. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. *Gynecol Oncol*. 1992 Jun;45(3):284-9. DOI: 10.1016/0090-8258(92)90305-3, PMID: 1612505.
 25. Bertelsen K, Jakobsen A, Strøyer J, Nielsen K, Sandberg E, Andersen JE, Ahrons S, Nyland M, Hjortkjaer Pedersen P, Larsen G, et al. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). *Gynecol Oncol*. 1993 Apr;49(1):30-6. DOI: 10.1006/gyno.1993.1081, PMID: 8482557.
 26. Lambert HE, Rustin GJ, Gregory WM, Nelstrop AE. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study. *Ann Oncol*. 1997 Apr; 8(4):327-33. DOI: 10.1023/a:1008256431090, PMID: 9209661.
 27. Zanotti KM, Belinson JL, Kennedy AW, Webster KD, Markman M. Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy. *Gynecol Oncol*. 2000 Nov; 79(2):211-5. DOI: 10.1006/gyno.2000.5958, PMID: 11063646.
 28. Markman M, Hakes T, Barakat R, Curtin J, Almadrones L, Hoskins W. Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: paclitaxel in refractory ovarian cancer. *J Clin Oncol*. 1996 Mar; 14(3):796-9. DOI: 10.1200/JCO.1996.14.3.796, PMID: 8622026.
 29. Attard G, Parker C, Eeles RA, Schröder F, Tomlins SA, Tannock I, Drake CG, de Bono JS. Prostate cancer. *Lancet*. 2016 Jan 2; 387(10013):70-82. DOI: 10.1016/S0140-6736(14)61947-4, PMID: 26074382.
 30. Sartor O, de Bono JS. Metastatic Prostate Cancer. *N Engl J Med*. 2018 Apr 26;378(17):1653-1654. DOI: 10.1056/NEJM1803343. PMID: 29694820.
 31. Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, Sonpavde G, Sternberg CN, Yegnasubramanian S, Antonarakis ES. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. *Eur Urol*. 2019 Jan; 75(1):88-99. DOI: 10.1016/j.eururo.2018.03.028, PMID: 29673712.
 32. Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, Huang J, True L, Gleave ME, Soule H, Logothetis C, Rubin MA. Aggressive variants of castration-resistant prostate cancer. *Clin Cancer Res*. 2014 Jun 1;20(11):2846-50. DOI: 10.1158/1078-0432.CCR-13-3309, PMID: 24727321.
 33. Labrecque MP, Coleman IM, Brown LG, True LD, Kollath L, Lakely B, Nguyen HM, Yang YC, da Costa RMG, Kaipainen A, Coleman R, Higano CS, Yu EY, Cheng HH, Mostaghel EA, Montgomery B, Schweizer MT, Hsieh AC, Lin DW, Corey E, Nelson PS, Morrissey C. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. *J Clin Invest*. 2019 Jul 30; 129(10):4492-4505. DOI: 10.1172/JCI128212. PMID: 31361600.
 34. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoco P, Thall PF, Logothetis CJ. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. *Clin Cancer Res*. 2013 Jul 1; 19(13):3621-30. DOI: 10.1158/1078-0432.CCR-12-3791, PMID: 23649003; PMCID: PMC3699964.
 35. Fitzpatrick JM, de Wit R. Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer. *Eur Urol*. 2014 Jun; 65(6):1198-204. DOI: 10.1016/j.eururo.2013.07.022, 23910941.
 36. Darshan MS, Loftus MS, Thadani-Mulero M, Levy BP, Escuin D, Zhou XK, Gjyzezi A, Chanel-Vos C, Shen R, Tagawa ST, Bander NH, Nanus DM, Giannakakou P. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. *Cancer Res*. 2011 Sep 15; 71(18):6019-29. DOI: 10.1158/0008-5472.CAN-11-1417, PMID: 21799031.
 37. Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Kyprianou N. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. *Cancer Res*. 2010 Oct 15; 70(20):7992-8002. DOI: 10.1158/0008-5472.CAN-10-0585, PMID: 20807808.
 38. Lohiya V, Aragon-Ching JB, Sonpavde G. Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic

- Castration-Resistant Prostate Cancer. Clin Med Insights Oncol. 2016 Oct 9;10 (Suppl 1):57-66. DOI: 10.4137/CMO.S34535, PMID: 27773999.
39. Antonarakis ES, Armstrong AJ. Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2011 Sep; 14(3):192-205. DOI: 10.1038/pcan.2011.23, PMID: 21577234.
40. Hager S, Ackermann CJ, Joerger M, Gillessen S, Omlin A. Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review. Ann Oncol. 2016 Jun; 27(6):975-984. DOI: 10.1093/annonc/mdw156, PMID: 27052650.
41. Ruiz de Porras V, Wang XC, Palomero L, Marin-Aguilera M, Solé-Blanch C, Indacochea A, Jimenez N, Bystrup S, Bakht M, Conteduca V, Piulats JM, Buisan O, Suarez JF, Pardo JC, Castro E, Olmos D, Beltran H, Mellado B, Martinez-Balibrea E, Font A, Aytes A. Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. Eur Urol. 2020 Nov 2:S0302-2838(20)30778-8. DOI: 10.1016/j.eururo.2020.10.001, PMID: 33153817.
42. Zagouri F, Korakiti AM, Zakopoulou R, Kyriazoglou A, Zografos E, Haidopoulos D, Apostolidou K, Papatheodoridi MA, Dimopoulos MA. Taxanes during pregnancy in cervical cancer: A systematic review and pooled analysis. Cancer Treat Rev. 2019 Sep; 79:101885. DOI: 10.1016/j.ctrv.2019.08.001, PMID: 31442939.
43. Bland KA, Kirkham AA, Bovard J, Shenkier T, Zucker D, McKenzie DC, Davis MK, Gelmon KA, Campbell KL. Effect of Exercise on Taxane Chemotherapy-Induced Peripheral Neuropathy in Women with Breast Cancer: A Randomized Controlled Trial. Clin Breast Cancer. 2019 Dec; 19(6):411-422. DOI: 10.1016/j.clbc.2019.05.013, PMID: 31601479.
44. Nabholz JM, Gligorov J. The role of taxanes in the treatment of breast cancer. Expert Opin Pharmacother. 2005 Jun;6(7):1073-94. doi: 10.1517/14656566.6.7.1073, PMID: 15957963.
45. Fernandes R, Mazzarello S, Joy AA, Pond GR, Hilton J, Ibrahim MFK, Canil C, Ong M, Stober C, Vandermeer L, Hutton B, da Costa M, Damaraju S, Clemons M. Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study. Support Care Cancer. 2018 Sep;26(9):3073-3081. DOI: 10.1007/s00520-018-4161-x. PMID: 29564623.
46. Chiu N, Chiu L, Chow R, Lam H, Verma S, Pasetka M, Chow E, DeAngelis C. Taxane-induced arthralgia and myalgia: A literature review. J Oncol Pharm Pract. 2017 Jan; 23(1):56-67. DOI: 10.1177/1078155215627502. Epub 2016 Jun 23. PMID: 26811404.
47. Malayeri, R, Berger T, Doppel bauer, A, Krajnik, G, Huber, H, & Pirker, R, 26 P - Monitoring of neurotoxicity of taxanes. European Journal of Cancer, 1996; 32, S6. DOI: 10.1016/0959-8049(96)84785-X.
48. Markman M. Managing taxane toxicities. Support Care Cancer. 2003 Mar; 11 (3):144-7. DOI: 10.1007/s00520-002-0405-9, PMID: 12618923.

Source of Support: None declared.

Conflict of Interest: None declared.

For any question relates to this article, please reach us at: editor@globalresearchonline.net

New manuscripts for publication can be submitted at: submit@globalresearchonline.net and submit_ijpsrr@rediffmail.com

